Concepedia
Statistics
Publications
6
Citations
1.2K
H-Index
Active since
2015
Affiliations
Pfizer (United States)(Current)
Probity Medical Research
Innovaderm (Canada)
Radboud University Nijmegen
Landeskrankenhaus Feldkirch
Jocelyne Papacharalambous is an author at Pfizer (United States) specializing in pharmacology, clinical pharmacology, and medicine.
Publications per year
2015–2021
Topical tofacitinib for atopic dermatitis: a phase <scp>II</scp> a randomized trial
Robert Bissonnette, Kim Papp, Yves Poulin et al. · British Journal of Dermatology · 2016 · 418 citations · Full text
Life Sciences, Dermatology, Pharmacology +15
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
H. Bachelez, P.C.M. van de Kerkhof, Robert Strohal et al. · The Lancet · 2015 · 394 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +8
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis
Melinda Gooderham, Seth Forman, Robert Bissonnette et al. · JAMA Dermatology · 2019 · 237 citations · Full text
Medicine, Dermatology, Pharmacology +11
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial
Seth Forman, David M. Pariser, Yves Poulin et al. · Journal of Investigative Dermatology · 2020 · 105 citations
Medicine, Pharmacology, Pharmacotherapy +14
Patient-Reported Symptoms and Disease Impacts in Adults With Moderate-to-Severe Atopic Dermatitis: Results From a Phase 2b Study With Abrocitinib
Eric L. Simpson, Andreas Wollenberg, Robert Bissonnette et al. · Dermatitis · 2021 · 22 citations
Medicine, Dermatology, Pharmacology +13
1–5 of 6